Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A critical role for Lyn in acute myeloid leukemia
Cédric Dos Santos, Cécile Demur, Valérie Bardet, et al.
Blood (2007) Vol. 111, Iss. 4, pp. 2269-2279
Open Access | Times Cited: 151

Showing 1-25 of 151 citing articles:

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
Sophie Park, Nicolas Chapuis, Jérôme Tamburini, et al.
Haematologica (2009) Vol. 95, Iss. 5, pp. 819-828
Open Access | Times Cited: 285
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
Lise Willems, Nathalie Jacque, Arnaud Jacquel, et al.
Blood (2013) Vol. 122, Iss. 20, pp. 3521-3532
Open Access | Times Cited: 270
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
Alberto M. Martelli, Camilla Evangelisti, Francesca Chiarini, et al.
Oncotarget (2010) Vol. 1, Iss. 2, pp. 89-103
Open Access | Times Cited: 247
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
Lise Willems, Jérôme Tamburini, Nicolas Chapuis, et al.
Current Oncology Reports (2012) Vol. 14, Iss. 2, pp. 129-138
Closed Access | Times Cited: 193
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
Sophie Park, Nicolas Chapuis, Valérie Bardet, et al.
Leukemia (2008) Vol. 22, Iss. 9, pp. 1698-1706
Closed Access | Times Cited: 191
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
Jérôme Tamburini, Alexa S. Green, Valérie Bardet, et al.
Blood (2009) Vol. 114, Iss. 8, pp. 1618-1627
Open Access | Times Cited: 184
Functions of the Lyn tyrosine kinase in health and disease
Evan Ingley
Cell Communication and Signaling (2012) Vol. 10, Iss. 1, pp. 21-21
Open Access | Times Cited: 161
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
Annelies G. Renner, Cédric Dos Santos, Christian Récher, et al.
Blood (2009) Vol. 114, Iss. 3, pp. 659-662
Closed Access | Times Cited: 142
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
Alberto M. Martelli, Francesca Chiarini, Camilla Evangelisti, et al.
Oncotarget (2012) Vol. 3, Iss. 4, pp. 371-394
Open Access | Times Cited: 119
Identification of Bruton’s tyrosine kinase as a therapeutic target in acute myeloid leukemia
Stuart A. Rushworth, Megan Y. Murray, Lyubov Zaitseva, et al.
Blood (2013) Vol. 123, Iss. 8, pp. 1229-1238
Open Access | Times Cited: 109
Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
Kalpana K. Bhanumathy, Balagopal Amrutha, Frederick S. Vizeacoumar, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 184-184
Open Access | Times Cited: 59
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia
Xiaoyan Hu, Lin Li, Jewel Nkwocha, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Multiple roles of Lyn kinase in myeloid cell signaling and function
Patrizia Scapini, Shalini Pereira, Hong Zhang, et al.
Immunological Reviews (2009) Vol. 228, Iss. 1, pp. 23-40
Open Access | Times Cited: 130
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia
Nathalie Gallay, Cédric Dos Santos, Lise Cuzin, et al.
Leukemia (2009) Vol. 23, Iss. 6, pp. 1029-1038
Closed Access | Times Cited: 122
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia
Alberto M. Martelli, Camilla Evangelisti, Francesca Chiarini, et al.
Expert Opinion on Investigational Drugs (2009) Vol. 18, Iss. 9, pp. 1333-1349
Closed Access | Times Cited: 114
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
Nicolas Chapuis, Jérôme Tamburini, Alexa S. Green, et al.
Leukemia (2010) Vol. 24, Iss. 10, pp. 1686-1699
Closed Access | Times Cited: 111
Inhibitor and activator: dual functions for SHIP in immunity and cancer
William G. Kerr
Annals of the New York Academy of Sciences (2010) Vol. 1217, Iss. 1, pp. 1-17
Open Access | Times Cited: 109
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents
Cédric Dos Santos, Tinisha McDonald, Yin Wei Ho, et al.
Blood (2013) Vol. 122, Iss. 11, pp. 1900-1913
Open Access | Times Cited: 98
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells
Christoph K. Weber, Thiemo B. Schreiber, Henrik Daub
Journal of Proteomics (2011) Vol. 75, Iss. 4, pp. 1343-1356
Closed Access | Times Cited: 86
Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium
C. Michel Zwaan, Carmelo Rizzari, Françoise Méchinaud, et al.
Journal of Clinical Oncology (2013) Vol. 31, Iss. 19, pp. 2460-2468
Open Access | Times Cited: 86
A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivo
Yoriko Saito, Hitomi Yuki, M. Kuratani, et al.
Science Translational Medicine (2013) Vol. 5, Iss. 181
Closed Access | Times Cited: 84
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders
Tadeusz Robak, Ewa Robak
Expert Opinion on Investigational Drugs (2012) Vol. 21, Iss. 7, pp. 921-947
Closed Access | Times Cited: 79
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
Héléna Boutzen, Estelle Saland, Clément Larrue, et al.
The Journal of Experimental Medicine (2016) Vol. 213, Iss. 4, pp. 483-497
Open Access | Times Cited: 75
WDR5 high expression and its effect on tumorigenesis in leukemia
Zheng Ge, E Song, Yuka Imamura Kawasawa, et al.
Oncotarget (2016) Vol. 7, Iss. 25, pp. 37740-37754
Open Access | Times Cited: 65
Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells
Johanna Congleton, Richard G. MacDonald, Andrew Yen
Leukemia (2011) Vol. 26, Iss. 6, pp. 1180-1188
Open Access | Times Cited: 68
Page 1 - Next Page

Scroll to top